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Abstract
Background: Several recent trials indicate low-dose ketamine produces rapid antidepressant effects. However, uncertainty 
remains in several areas: dose response, consistency across patient groups, effects on suicidality, and possible biases arising 
from crossover trials.
Methods: A systematic search was conducted for relevant randomized trials in Medline, Embase, and PsycINFO databases 
up to August 2014. The primary endpoints were change in depression scale scores at days 1, 3 and 7, remission, response, 
suicidality, safety, and tolerability. Data were independently abstracted by 2 reviewers. Where possible, unpublished data were 
obtained on treatment effects in the first period of crossover trials.
Results: Nine trials were identified, including 201 patients (52% female, mean age 46 years). Six trials assessed low-dose ketamine 
(0.5 mg/kg i.v.) and 3 tested very low-dose ketamine (one trial assessed 50 mg intra-nasal spray, another assessed 0.1–0.4 mg/kg i.v., 
and another assessed 0.1–0.5 mg/kg i.v., intramuscular, or s.c.). At day 3, the reduction in depression severity score was less marked 
in the very low-dose trials (P homogeneity <.05) and among bipolar patients. In analyses excluding the second period of crossover 
trials, response rates at day 7 were increased with ketamine (relative risk 3.4, 95% CI 1.6–7.1, P = .001), as were remission rates 
(relative risk 2.6, CI 1.2–5.7, P = .02). The absolute benefits were large, with day 7 remission rates of 24% vs 6% (P = .02). Seven trials 
provided unpublished data on suicidality item scores, which were reduced on days 1 and 3 (both P < .01) but not day 7.
Conclusion: Low-dose ketamine appears more effective than very low dose. There is substantial heterogeneity in clinical 
response, with remission among one-fifth of patients at 1 week but most others having benefits that are less durable. Larger, 
longer term parallel group trials are needed to determine if efficacy can be extended and to further assess safety.
Keywords: Ketamine, major depression, meta-analysis








2 | International Journal of Neuropsychopharmacology, 2016
Introduction
Aside from electro-convulsive therapy (ECT), there are no 
widely used treatments that provide large or rapid benefits 
for patients suffering from severe depression (Martinowich 
et  al., 2013). This presents a major clinical challenge, espe-
cially for patients who have not responded fully to existing 
therapy or if symptoms include suicidality. In 2000 a small 
crossover trial suggested that a single subanaesthetic dose of 
ketamine could provide a large antidepressant benefit, start-
ing within a few hours and lasting for at least several days 
(Berman et al., 2000). Ketamine appeared to improve specific 
depressive symptoms such as sadness, suicidality, and help-
lessness, rather than induce a nonspecific mood-elevating 
effect. Since then, several more trials have been published 
(Zarate et  al., 2006; Diazgranados et  al., 2010a; Zarate et  al., 
2012; Murrough et  al., 2013; Sos et  al., 2013), but existing 
reports and reviews (aan het Rot et  al., 2010; Aan Het Rot 
et al., 2012; Katalinic et al., 2013; Brittner et al., 2014; Caddy 
et  al., 2014; McGirr et  al., 2014) do not easily allow a direct 
comparison of how treatment effects persist in the days fol-
lowing treatment, given differences in graphical and tabular 
reporting methods and outcome scales. Three very recently 
reported trials (Lai et al., 2014; Lapidus et al., 2014) (C. K. Loo, 
V. Galvez, E. O’Keefe, unpublished data) evaluated lower doses 
of ketamine than previously tested, providing an opportu-
nity to compare treatment efficacy and tolerability of differ-
ent doses. One other key issue is the extent of bias resulting 
from the use of a crossover design in all but one previous trial. 
Potential biases from crossover designs, such as carryover of 
treatment effect into the second treatment period, can be 
addressed by restricting analyses to the first treatment period 
but often requires unpublished data. We therefore conducted 
a systematic review of trials of ketamine in patients with 
treatment-resistant depression to evaluate antidepressant 
efficacy, suicidality, safety, and tolerability.
Methods
Types of Trials
We considered all relevant randomized trials (either crossover or 
parallel) in which ketamine was used specifically for the treat-
ment of a Major Depressive Episode (DSM-IV diagnosis) and was 
compared with placebo, including active placebo. Eligible trials 
included participants with either unipolar or bipolar affective 
disorder. We excluded trials conducted in the context of ECT and 
surgery, but there were no restrictions on concomitant pharma-
cological or psychological treatments.
Types of Interventions
We included any trial that attempted to evaluate a comparison 
between single administration of ketamine and placebo for the 
treatment of major depressive disorder. There was no restriction 
on ketamine regimen used (eg, dose or route).
Types of Outcome Measures
The primary endpoint was change in depression severity scores 
from baseline on depression scales such as the Hamilton 
Depression Rating Scale (HAM-D; Hamilton, 1960) and/or the 
Montgomery Åsberg Depression Rating Scale [MADRS]) at the 
following times: day 1 (24 hours after first dose), day 3, and day 
7. Other outcomes were: clinical remission (defined as HAM-D 
<7 or MADRS <10); clinical response (defined as ≥50% reduction 
in depression severity score); suicidality measures, including 
the suicidality item of HAM-D or MADRS; safety and tolerability 
as assessed by reported adverse events and dropouts.
Search Methods for Identification of Trials
Reports were restricted to English language publications. 
Publications for this review were identified by searching 
Medline, Embase, and PsycINFO databases before August 2014 
using the following search terms as free text or subject head-
ings as appropriate for each database: (“ketamine” OR “NMDA 
receptor antagonist”) AND (“depression” OR “major depressive 
disorder” OR “bipolar depression” OR “depressive disorder” OR 
“dysthymic disorder” OR “treatment resistant depression”) AND 
(“ randomized controlled trial” OR “controlled clinical trial” OR 
“randomized” OR “placebo”) (full details available in supplemen-
tary Table 1 in the online data supplement). If additional studies 
cited in these articles met with these criteria, then they were 
also included.
Selection of Studies
Two authors (A.R.  and Y.X.) reviewed the search strategy and 
selected studies for inclusion in the review. In case of disagree-
ment, M.H. arbitrated.
Data Extraction and Analysis
When relevant publications were selected, 2 authors (A.R. and 
Y.X.) independently extracted information on year of publica-
tion, geographic location, sample size, loss to follow-up, mean 
age, study design, major inclusion and exclusion criteria, con-
comitant treatments, and outcome measures as well as safety 
and tolerability.
Potential sources of bias were identified for each trial 
using criteria recommended in the Cochrane Handbook 
(Higgins and Green, 2009). For random sequence generation, 
we categorized trials as “low risk” if random-number charts or 
coin tossing was used, as “unclear” if there were no details of 
sequence generation, and as “high risk” if sequence was gen-
erated by odd/even date of birth. For allocation concealment, 
we categorized trials as low risk if opaque or sealed envelopes 
were used, as unclear if there was no detailed information 
and as high risk if assignments could possibly be foreseen. 
For blinding, we categorized studies as low risk if blinding was 
ensured and unlikely to be broken, as unclear if an inactive 
placebo was used, and as high risk if outcome measurement 
was likely to be influenced by lack of blinding. For incomplete 
outcome data, we categorized trials as low risk if missing 
outcome data balanced in numbers and with similar reasons 
across intervention groups, as unclear if reports of drop- outs 
were insufficient, and as high risk if there were imbalances 
in numbers or reasons for missing data across intervention 
groups. For selective reporting, we categorized trials as low 
risk if there was a published protocol and the outcome meas-
ures listed in the protocol were reported, as unclear if proto-
col could not be found and as high risk if a described outcome 
measure in the protocol or methods was not reported in 
results. Assessment of period and carryover effects were 
listed under “other sources of bias.” We categorized crossover 
trials as high risk and parallel trials as low risk.
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Depression severity score (HAM-D and/or MADRS) at each 
follow-up time point was calculated for each trial, for ketamine 
or placebo groups, and a placebo-corrected value for each time 
point was calculated. If not available in tabular form, HAM-D 
and/or MADRS results at different time points were estimated 
independently from Figureures in the articles by 2 authors. 
Placebo-corrected HAM-D scores were plotted separately for 
each trial with that outcome measure, and placebo-corrected 
MADRS scores for all trials with that outcome measure. In 
addition, we plotted a percentage reduction in depression 
severity score for all trials based on MADRS score where avail-
able and HAM-D for other trials. We conducted a meta-analysis 
of mean MADRS score at day 1, 3, and 7, with day of administra-
tion defined as day 0. These analyses were conducted initially 
to include the data from the single parallel trial and the first 
period of all crossover trials. We also compared the relative risk 
(RR) during the first period against the second period in crosso-
ver trials in order to examine the direction and magnitude of 
carryover effects. Meta-analysis of continuous outcomes was 
conducted using Stata13 (www.stata.com), Windows 7.  Meta-
analyses of response rates and clinical remission at days 1, 
3, and 7 were conducted using Review Manager Version 5.3. 
software (RevMan, 2014) to estimate RR and number needed 
to treat (NNT). All meta-analyses were done using a random 
effects model. The I2 statistic was used to assess heterogeneity 
of trial results, and subgroup heterogeneity was tested using 
a chi-squared statistic (Higgins and Green, 2009). Data were 
available only on day 4 for one trial (Sos et al., 2013), and this 
was included in the day 3 category. Data were sought from the 
crossover trials for each treatment period separately.
Results
Search Results
The search results and study selection process are summarized 
in a PRISMA flowchart (Figure 1) showing the number of unique 
references identified by the search, the number of records 
excluded, and the number of full-text records retrieved. One 
placebo-controlled trial was not included because the sequence 
was not randomized (Valentine et al., 2011) and one randomized 
trial was not included because ketamine was compared with 
ECT (Ghasemi et al., 2014). One unpublished trial of the effects of 
intra-operative ketamine on depression was identified, but data 
were not available (M. Bastos, personal communication).
Baseline Characteristics
Nine randomized, placebo-controlled trials were identified, 
and a total of 201 patients (105 females and 96 males) were 
Figure 1. Flow diagram for systematic review.
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included (Table 1) (Berman et al., 2000; Zarate et al., 2006, 2012; 
Diazgranados et  al., 2010a; Murrough et  al., 2013; Sos et  al., 
2013; Lai et al., 2014; Lapidus et al., 2014) (C. K. Loo, V. Galvez, 
E. O’Keefe, unpublished data). Eight studies (Berman et al., 2000; 
Zarate et al., 2006, 2012; Diazgranados et al., 2010a; Sos et al., 
2013; Lai et al., 2014; Lapidus et al., 2014) (C. K. Loo, V. Galvez, 
E.  O’Keefe, unpublished data) were crossover trials with a 1- 
to 2-week washout period between treatments, and one was a 
parallel group design with 1 week of follow-up (Murrough et al., 
2013). Two trials (Diazgranados et al., 2010a; Zarate et al., 2012) 
included only patients with bipolar disorder (BD), and 7 trials 
(Berman et al., 2000; Zarate et al., 2006; Murrough et al., 2013; 
Sos et al., 2013; Lai et al., 2014; Lapidus et al., 2014) (C. K. Loo, 
V.  Galvez, E.  O’Keefe, unpublished data) included patients 
with only unipolar depression (although one trial [Berman 
et  al., 2000] included one patient with BD). All patients were 
treatment resistant, variously defined (Table 1). Patients with 
history of psychosis or recent substance use disorders were 
generally excluded. Patients in the 2 BD trials (Diazgranados 
et al., 2010a; Zarate et al., 2012) were drug free except for lith-
ium or valproate. In the other 7 trials, patients were drug free 
in 2 (Berman et al., 2000; Zarate et al., 2006), allowed to take 
only a nonbenzodiazepine hypnotic in one (Murrough et  al., 
2013), and taking stable doses of other psychotropic medica-
tions in 4 trials (Sos et al., 2013; Lai et al., 2014; Lapidus et al., 
2014) (C. K. Loo, V. Galvez, E. O’Keefe, unpublished data). Six tri-
als (Berman et al., 2000; Zarate et al., 2006, 2012; Diazgranados 
et al., 2010a; Murrough et al., 2013; Sos et al., 2013) assessed a 
single 40-minute infusion of i.v. ketamine at a subanaesthetic 
low dose of 0.5 mg/kg (defined here as low dose). Three tri-
als tested lower doses (defined here as very low-dose trials): 
50 mg intranasally (as 10 mg every 5 minutes), estimated to 
achieve plasma concentrations equivalent to about 0.3 mg/kg 
i.v. (Lapidus et al., 2014); 0.1 to 0.4 mg/kg i.v. (Lai et al., 2014), or 
0.1 to 0.5 mg/kg i.v., intramuscular, or s.c. in an ascending dose 
design (with placebo randomly inserted) (C. K. Loo, V. Galvez, 
E. O’Keefe, unpublished data). Seven trials (Berman et al., 2000; 
Zarate et al., 2006, 2012; Diazgranados et al., 2010a; Sos et al., 
2013; Lai et  al., 2014; Lapidus et  al., 2014) used 0.9% saline 
as placebo and 2 used 0.045 mg/kg (Murrough et  al., 2013) or 
0.01 mg/kg (C. K. Loo, V. Galvez, E. O’Keefe, unpublished data) 
midazolam as an active placebo. Potential sources of bias are 
summarized in Figure 2.
Effects on Depression Severity Scores over Time
Effects on depression severity over time are presented in 
Figure 3, with data redrawn from original trials and placed on 
a uniform linear scale, and shown in Figure 4 with data from 
the single parallel trial and from the first period of crossover 
trials. A  large reduction in depression severity was evident 
within 4 hours in all but one small trial of very low-dose keta-
mine, and treatment effects were largest at day 1.  In the tri-
als of very low-dose ketamine (Lai et al., 2014; Lapidus et al., 
2014) (C. K. Loo, V. Galvez, E. O’Keefe, unpublished data), the 
reduction in overall severity appeared smaller and shorter 
lived. A  test for heterogeneity indicated a significant differ-
ence in treatment effects at day 3 for low-dose compared with 
very low-dose trials (P = .02). In the 4 trials conducted with 
ketamine 0.5 mg/kg i.v. for patients with unipolar depression 
(Berman et al., 2000; Zarate et al., 2006; Murrough et al., 2013; 
Sos et al., 2013), the large reduction in average mood score at 
24 hours remained evident, though moderately attenuated, up 
to day 7. In the 2 trials among patients with BD, the treatment 
effect largely dissipated by days 4 to 7 (Diazgranados et  al., 
2010a; Zarate et  al., 2012). A  smaller treatment effect in BD 
patients compared with unipolar patients on the HAM-D was 
evident by 24 hours. There was no evidence of greater benefit 
in trials that aimed to attain high peak concentrations, either 
with an i.v. push during a few minutes (Lai et al., 2014) or an 
initial loading dose of 0.27 mg/kg during the first 10 minutes 
(Sos et al., 2013).
Effects on Response and Remission Rates over Time
Analyses of treatment effects on response and remission, 
including only the single parallel group trial and the first treat-
ment period of crossover trials, are summarized in Figure 5. At 
day 1, there was a large treatment effect, with 50% of those in 
the ketamine group compared with 13% in the placebo group 
meeting criteria for response (RR 2.6, 95% CI 1.6 to 4.4, P = .0003; 
NNT 2.9, 1.9–7.1). There was a similarly large effect on remis-
sion of symptoms at day 1 (RR 5.2, 95% CI 2.1–12.9, P = .0003; NNT 
4.5, 3.1–8.3) among those receiving ketamine. At day 7, response 
rates were substantially increased in the ketamine group and to 
a larger degree (RR 3.4, 95% CI 1.6 to 7.1, P = .001; NNT 6.3, 3.4–25). 
Remission rates were still substantially increased in the keta-
mine group, although to a lesser degree (RR 2.6, 95% CI 1.2–5.7, 
P = .02; NNT 9.1, 5–50). While the pooled results of 3 trials of very 
low-dose ketamine showed no significant effect on response or 
remission on days 1, 3, or 7 and the treatment effect appeared 
smaller compared to low-dose ketamine, formal subgroup het-
erogeneity tests were not significant (P = .09 for response and 
P = .12 for remission on day 3).
One of the major potential biases in crossover trials is drop-
out after the first treatment, and this occurred in 12/46 patients 
who received ketamine initially compared with 5/55 who 
received placebo initially in 5 trials (Zarate et  al., 2006, 2012; 
Diazgranados et al., 2010a; Sos et al., 2013; Lapidus et al., 2014). 
Dropout was for improved mood for 4 patients in the ketamine 
group and 2 in the placebo group. In terms of treatment effects 
in the second period of the crossover trials, overall 0/34 patients 
responded at day 1 who received placebo as their second treat-
ment compared with 22/50 patients responding at day 1 after 
receiving ketamine as their second treatment. Remission was 
achieved in 0/34 patients at day 1 who received placebo as their 
second treatment compared with 8/50 patients after receiving 
ketamine as their second treatment. Thus, it did appear that 
carryover effects were not marked, although this cannot be 
assessed reliably since fewer patients in the ketamine groups 
proceeded to the second period.
Effects on Suicidality
Measures of suicidality were published in 4 trials (Berman 
et al., 2000; Zarate et al., 2006, 2012; Murrough et al., 2013) and 
these are summarized in Table 2. Each trial reported a signifi-
cant reduction in suicidality assessed using different measures. 
Seven trials provided unpublished data on the suicide item com-
ponent of a depression scale, 1 for HAM-D (Zarate et al., 2006), 
and 6 for MADRS (Diazgranados et al., 2010a; Zarate et al., 2012; 
Sos et al., 2013; Lai et al., 2014; Lapidus et al., 2014) (C. K. Loo, 
V. Galvez, E. O’Keefe, unpublished data). Overall, reported suici-
dality scores were low at baseline, with an average of 1.6 on the 
MADRS suicidality item (which ranges from 0 to 6) for trials that 
reported this outcome, as shown in Table 3. Nonetheless, a sig-
nificant reduction in suicidality severity score was observed for 
the ketamine group at days 1 and 3, as seen in Figure 6.
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Tolerability and Side Effects
Measures of tolerability and side effects were summarized 
in Table  4. Low-dose ketamine at 0.5 mg/kg, infused over 40 
minutes, was generally well tolerated, with transient, mild-
to-moderate dissociative symptoms and blood pressure and/
or heart rate increases in a minority of patients. For example, 
in the largest trial, 17% of patients had significant dissociative 
symptoms immediately after ketamine infusion, but these all 
resolved within 2 hours and no severe psychotic symptoms 
(paranoia, hallucinations, or delusions) occurred in either arm 
(Murrough et  al., 2013). The characteristic symptomatic side 
effects (eg, confusion, blurred vision) and the increases in heart 
rate and blood pressure resolved within 4 hours of adminis-
tration in all trials. These side effects were less marked with 
very low-dose ketamine delivered intranasally for 20 minutes 
(Lapidus et  al., 2014) but were more marked with very low-
dose ketamine given as an i.v. push for a few minutes (Lai 
et al., 2014). Among trials that reported a full listing of adverse 
events in both groups, there was no excess in the ketamine 
vs placebo after administration day (Murrough et al., 2013; Lai 
et al., 2014; Lapidus et al., 2014) (C. K. Loo, V. Galvez, E. O’Keefe, 
unpublished data).
Eleven events were reported as serious adverse events in 
the ketamine group: hypotension and bradycardia occurred 
in 1 person, which resolved in <1 minute and was considered 
to be due to a vaso-vagal episode (Murrough et al., 2013); sui-
cide attempt occurred in 1 patient while tapering off of psy-
chotropic medication (Murrough et al., 2013); tachycardia (>150 
bpm) occurred in 2 patients (Lai et al., 2014); and mean arterial 
pressure elevations >20% from baseline in 5 patients (Lai et al., 
2014) (C. K. Loo, V. Galvez, E. O’Keefe, unpublished data). Also, 
while not reported as serious adverse events, one ketamine-
treated patient developed manic symptoms that resolved 
within 80 minutes, and an affective switch occurred for one 
patient in the placebo group (Diazgranados et  al., 2010a). All 
the hemodynamic side effects resolved within a few hours with 
no lasting effects. Thus, it could be summarized that 3 major 
psychiatric events (suicide attempt before treatment, transient 
manic symptoms, and affective switch) were reported in the 
studies, of which only one was potentially attributable to keta-
mine (transient manic symptoms). No major medical events 
occurred in the trials.
Diverse measures were used to test possible psychotomi-
metic, dissociative, or mood elevation symptoms, including 
Visual Analogue Scale score for intoxication “high” (Aitken, 
1969), Brief Psychiatric Rating Scale (Overall and Gorham, 1962), 
Young Mania Rating Scale (Young et  al., 1978), and Clinician 
Administered Dissociative States Scale (Bremner et  al., 1998). 
The results showed that Visual Analogue Scale score for intoxi-
cation “high” scores returned to baseline within 110 minutes 
of the infusion (Berman et  al., 2000). In no case did euphoria, 
derealization, or depersonalization persist beyond 110 minutes 
(Zarate et al., 2006).
Continuation into the second phase of the crossover trial 
was also assessed as a proxy of tolerability, and most dropouts 
were reported as being due to changes in mood rather than 
adverse events. In 5 crossover trials with first-phase data avail-
able (Zarate et  al., 2006, 2012; Diazgranados et  al., 2010a; Sos 
et al., 2013; Lapidus et al., 2014), 12 of 46 patients did not pro-
ceed to placebo treatment after receiving ketamine first. For 4 
patients, this was due to improved mood (Zarate et al., 2006), for 
4 it was due to worsening mood (Diazgranados et al., 2010a; Sos 
et al., 2013), and other reasons were involved for an additional 4 
(Zarate et al., 2012; Lapidus et al., 2014).
Discussion
Summary of Findings
This systematic review of trials of single-dose ketamine com-
pared with placebo for treatment-resistant patients in a major 
depressive episode confirms a large reduction in depression 
severity and suicidality that is apparent within 4 hours after 
Figure 2. Potential sources of bias in included trials. See Methods for explanation of potential biases.
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ketamine administration. The data suggest benefits are smaller 
and shorter lived with very low-dose ketamine. There is also a 
suggestion of short-lived effects in patients with BD. There is 
substantial heterogeneity in clinical response, with benefits 
lasting <1 week for most patients, but approximately one-fifth 
of patients remaining in remission at 1 week.
Limitations
This systematic review has a number of methodological limi-
tations. Most important is the small sample size (average of 
only 23 patients per trial) and 201 patients in total. The use of a 
crossover design in all but one trial is a potential issue. While a 
crossover design improves study power to partly mitigate prob-
lems associated with small sample size, it can have limitations 
for mood disorder trials. Crossover designs are most reliable 
when assessing a fully reversible treatment, with outcomes 
that return to baseline levels after a suitable washout period 
(ie, short-lived interventions that do not affect the natural his-
tory of a stable illness). For treatments that do not have these 
criteria, one can observe period effects (ie, the treatment effect 
in the first period is systematically different from that in the 
second period) and/or carryover effects (ie, the treatment effect 
in the first period is still operating during the second period). 
Statistical tests to detect period and carryover effects are rela-
tively insensitive, and analytic approaches to overcome these 
issues are generally unsatisfactory (Senn, 2002). However, these 
issues can be addressed with a separate analysis of first period 
data, which was possible in this meta-analysis. Finally, all tri-
als involved one-off treatments and varying measures of side 
effects and had relatively short follow-up; hence, the safety and 
efficacy of long-term treatment remain uncertain.
Figure 3. Reductions in depression severity scores following single-dose ketamine in patients with major depression. (A) Placebo-corrected changes in Hamilton 
Depression Rating Sclae Scores (HAM-D). (B) Placebo-corrected changes in Montgomery-Åsberg Depression Rating Scale (MADRS). (C) Placebo-corrected percentage 
changes in HAM-D/MADRS. Data are placebo-corrected, and axes redrawn on a linear scale to avoid a visual misrepresentation of how the treatment effect evolves over 
time. Lines with circular markers represent trials among patients with bipolar disorder depression. Other trials were among patients with unipolar depression. Lines 
with square markers represent patients remained on pretrial antidepressant treatment. Solid lines represent low dose (i.v. ketamine 0.5 mg/kg). Dashed lines represent 
very low dose (intranasal ketamine 50 mg or i.v. 0.3 mg/kg; Lai et al. and Loo et al. used an ascending dose design and the data for 0.3 mg/kg are shown).
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Strengths of this review include the reporting of additional 
unpublished data from numerous trials and analyses of only 
the first treatment period, increasing the reliability. It is also 
the first review to compare results of low-dose and very low-
dose ketamine, suggesting larger benefits with the former. The 
consistency of the findings described in this review suggest 
a true treatment effect in improving depressive symptoms, 
albeit temporarily for most. Several additional strands of evi-
dence indicate that the benefit observed in these trials is a 
result of depression treatment, rather than nonspecific mood 
elevation or a ‘high’ following ketamine administration: there 
is improvement in core depressive symptoms such as sad-
ness, suicidality, and helplessness; the time course of ben-
efits is in the following days and sometimes weeks, whereas 
mood elevation with drugs of abuse is generally limited to 
the time of intoxication; the response pathway can be inter-
rupted in animal models of depression treatment (Autry et al., 
2011); and postoperative mood improvement occurs among 
patients given ketamine intra-operatively, who would have 
been unaware of immediate subjective effects (Kudoh et  al., 
2002; Argiriadou et al., 2004). Recent trials have also suggested 
possible benefits among patients with posttraumatic stress 
disorder (Whiteford et al., 2015) and in obsessive compulsive 
disorder (Rodriguez et al., 2013), and there is encouraging ini-
tial evidence comparing ketamine with ECT (Ghasemi et  al., 
2014).
Relevance for Clinical Practice and Research
Most clinicians, drug regulators, and health funders will require 
further research evidence before low-dose ketamine is adopted 
in clinical practice. The results of this review have several impli-
cations for future research.
First, research is urgently required on efficacy and safety 
of longer treatment regimens. A  key issue is whether the 
ketamine response can be maintained or even enhanced by 
repeated dosing, such as the 2 to 3 times weekly schedule that 
has been assessed in some case series with promising find-
ings (Price et al., 2009; aan het Rot et al., 2010; DiazGranados 
et  al., 2010b; Larkin and Beautrais, 2011; Rasmussen et  al., 
2013; Shiroma et  al., 2014). Safety, tolerability, and abuse 
potential of repeated dosing is a critical issue for future trials. 
While some reassurance can be taken from the much more 
extensive use of i.v., oral, and sublingual ketamine in chronic 
pain control (Chong et al., 2009), future longer term trials must 
assess safety in this patient population. Trials should assess 
the likelihood of abuse potiential in subjects with major 
depression, while incorporating strategies to mitigate this.
Second, trials should adopt parallel designs rather than 
crossover designs, since benefits remain for more than 1 week 
in a significant proportion of patients; hence, this situation 
does not meet the fundamental criterion for crossover trials 
to have a stable disease baseline and short-lived treatment 
effect in all patients. Third, trials should recruit many times 
more patients, so that the effects in different subgroups can 
be assessed reliably given the considerable heterogeneity in 
response. Fourth, trial designs should reflect the possibility 
of different effects among patients with bipolar and unipolar 
disorder. Fifth, there is no evidence concerning first-line treat-
ment of major depressive disorder: ketamine may have a role 
to play in patients with severe presenting symptoms, includ-
ing suicidality, and could conceivably cover the lag phase 
before SSRI efficacy onset (and reduction of suicidal ideation 
may be particularly important in young adults). Further evi-
dence of reduction in suicidality was recently provided by an 
additional trial published after our search cut-off date, con-
ducted among 27 patients with mood and anxiety spectrum 
disorders who presented with clinically significant suicidal 
ideation.(Murrough et al., 2015) Ketamine may also augment 
the response from standard treatments. For example, while 
ECT is indicated in severe depression with acute suicidality 
it may take a week or longer to alleviate symptoms and keta-
mine may play an important role by acting more quickly in 
this setting. Finally, further data on safety and efficacy of use 
in ‘real world’ clinical settings is clearly required, given that 
many of the trials were conducted in highly medically con-
trolled environments. While i.v. infusions may be practical in 
service settings used for ECT, other formulations and delivery 
routes, such as intranasal spray, s.c., intramuscular, or oral, 
are likely to be more broadly applicable to clinical practice. 
Minimizing dissociative and hemodynamic side effects is 
important for widespread applicability, and this is likely to 
Figure 4. Difference in standardized mean mood score on days 1, 3, and 7 for crossover trials, first period only. Data are shown only for the first period in crossover 
trials. Hamilton Depression Rating Sclae Scores (HAM-D) was reported by Zarate et al., 2006 with the remainder reporting Montgomery-Åsberg Depression Rating Scale 
(MADRS). 95% CIs of treatment effects are represented by horizontal lines for individual trials, by grey diamonds for trial subgroups, and by black diamonds for all 
trials. A vertical dashed line goes through the overall pooled result for all trials, with a result to the left of the vertical line indicating a reduction in mood score in the 
ketamine group.
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involve avoiding high peak plasma levels (Lai et  al., 2014). 
However, very low doses are associated with lower efficacy, 
suggesting multiple low doses delivered gradually or sequen-
tially may be optimal. Future trials could also assess ketamine 
enantiomers (Paul et  al., 2009), metabolites (Zarate Jr et  al., 
2012), or other glutamatergic agents.
Conclusions
This systematic review confirmed a large, rapid benefit in 
response and remission following a single dose of ketamine 
in patients with treatment resistant depression. There was 
also a reduction in suicidality. Transient psychotomimetic 
and heemodynamic effects occurred. There were no major 
medical events. Collectively, these data suggest ketamine 
has considerable promise for the acute treatment of major 
depression and provide the rationale for a large, parallel 
group, randomized, placebo-controlled trial to assess safety 
and efficacy of a longer course of ketamine in patients with 
severe mood disorders.
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Table 2. Published Measures of Suicidality
Trial Measure Used Outcome Reported in Publication
Berman et al., 2000 HAM-D suicidality item While undergoing active treatment, significant 
decreases were observed for suicidality (P < 
.02). Control treatment was not associated with 
significant improvement in any of the HAM-D 
items.
Zarate et al., 2006 HAM-D suicidality item Significant main effect for drug
Zarate et al., 2012 Changes in suicide item scores on the 
MADRS, HAM-D, and BDI
Within 40 min, suicidal ideation significantly 
improved in subjects receiving ketamine compared 
with placebo (Cohen’s d 0.98, 95% CI 0.64 –1.33); 
this improvement remained significant through 
day 3. Reductions in suicide item scores for each 
of the MADRS, HAM-D, and BDI using linear mixed 
models (each P  < .001)
Murrough et al., 2013 Composite index of explicit suicidal 
ideation (Beck Scale for Suicidal 
Ideation, MADRS suicide item, Quick 
Inventory of Depressive Symptoms 
suicide item)
Fifty-three percent of ketamine-treated patients 
scored 0 on all 3 explicit suicide measures at 
24 h compared with 24% of the midazolam group 
(χ = 4.6; P = .03)
Abbreviations: BDI, Beck Depression Inventory; HAM-D, Hamilton Depression Rating Scale; MADRS, Montgomery Åsberg Rating Scale.
Table 3. Unpublished Data on Suicidality Scores at Baseline
Trial Suicidality Item Subscale Used
Ketamine Placebo
Mean SD Mean SD
Zarate et al., 2006 HAM-D, item 4* 1.9 1.1 1.2 1.1
Diazgranados et al., 2010a MADRS, item 10** 2.0 1.9 2.4 1.9
Zarate et al., 2012 MADRS, item 10** 2.3 1.6 2.5 1.5
Sos et al., 2013 MADRS, item 10** 0.4 0.7 0.4 0.7
Lapidus et al., 2014 MADRS, item 10** 1.7 1.4 1.7 1.7
Lai et al., 2014 MADRS, item 10** 1.8 1.0 1.8 1.0
Loo et al., unpublished MADRS, item 10** 1.9 1.2 2.3 1.0
Abbreviations: MADRS, Montgomery Åsberg Rating Scale.
*Ranges from 0 to 4; **ranges from 0 to 6.
Figure 6. Standardized mean differences in suicide item scores at days 1, 3, and 7. Suicide item score from Hamilton Depression Rating Sclae Scores (HAM-D) provided 
by Zarate et al., 2006, and from Montgomery-Åsberg Depression Rating Scale (MADRS) for other trials. 95% CIls of treatment effects are represented by horizontal lines 
for individual trials and by diamonds for all trials. A vertical dashed line goes through the overall pooled result for all trials, with a result to the left of the vertical line 
indicating a reduction in mood suicide item score in the ketamine group.
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Table 4. Measures of Safety and Tolerability in Included Trials








two groups till 
40 min and return 




scores, especially the 
positive symptoms. 
Scores are significantly 
different between 2 
groups until 40 min 
and return to baseline 
by 120 min.
Not mentioned Not mentioned Not mentioned
Zerate  
et al., 2006
Not mentioned The positive symptoms 
subscale scores were 
worse for participants 
receiving ketamine 
than those receiving 
placebo only at 40 min.
Not mentioned Worse for participants 
receiving ketamine 
than placebo at 40 
minutes, but they 
were significantly 





Not mentioned Ketamine and placebo 
differed only at 
40 min, and this 
difference was due to 
a small, nonsignificant 
decrease with 
placebo and an even 




seen at 40 min only 
(large increase on 
ketamine).
Patients receiving 
ketamine had higher 
scores at 40 min but 
significantly lower 
scores at days 2 and 
14. Compared with 
baseline, there was 
no significant change 
in manic symptoms 
in patients receiving 
placebo.
One patient developed 
manic symptoms in 
the ketamine group 
that resolved within 
80 min and an affective 
switch occurred for 




Not mentioned No significant drug  
effect or interaction.
Higher values in 
patients receiving 
ketamine only at 
40 min.





Not mentioned The positive symptoms 
subscale scores for 
ketamine patients 
beyond the 40 min 
ranged from 4.02 to 
4.04.
At 40 min, the average 
score for the ketamine 
group was 14.7 (10.6–
18.8), and 2.28 (0.0–4.8) 
for the midazolam 
group. Average scores 
for the ketamine 
group beyond 40 min 
ranged between 0.065 
and 0.533.
The first item of the 
YMRS at 40 min was 
0.6 for ketamine and 
0.12 for midazolam 
group.
Patient 1: BP = 73/40 
(1 min) HR <30 bpm 
(30 sec), spontaneous 
recovery; Patient 
2: Suicide attempt 






Not mentioned No relationship between 
ketamine associated 
changes in dissociative 
or psychotomimetic 
symptoms and antide-










Measured, but not 
reported
Nil
Lai et al., 2014 Not mentioned Clear dose–response  
relationship for  
psychotomimetic 
symptoms occurring 
within 40 min. Scores 
returned to pre- 
treatment levels within 





within 40 min. Scores 
returned to pre-treat-
ment levels within 4h 
for all subjects.
Not mentioned During 0.4 mg/kg dosage 
Two patients:  
tachycardia (150 bpm);
One patient: BP increase 
(140/80 to 195/105). 
Spontaneous recovery 
within 15 min
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